We are live on ! Find out more
BCDA icon

BioCardia
BCDA

8 hedge funds and large institutions have $603K invested in BioCardia in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.04% less ownership

Funds ownership: 0.2% → 0.16% (-0.04%)

11% less funds holding

Funds holding: 9 → 8 (-1)

14% less capital invested

Capital invested by funds: $700K → $603K (-$97K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$11.2K
2
Morgan Stanley
Morgan Stanley
New York
+$2.53K
3
TRCT
Tower Research Capital (TRC)
New York
+$1.23K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$71K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$51K
3
Millennium Management
Millennium Management
New York
-$38.3K
4
AG
Advisor Group
Arizona
-$1.35K

BCDA Hedge Fund Activity: Q4 2019 in Review

8 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q4 2019, worth a combined $603K — down 14% from $700K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BCDA and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, opening a new position worth an estimated $11.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $71K sold.

  • 8 institutional investors held BioCardia (BCDA) as of Q4 2019, down from 9 in Q3 2019.
  • Funds reported $603K of BioCardia stock for Q4 2019, down 14% quarter-over-quarter.
  • 1 fund opened new BioCardia positions in Q4 2019 and 2 closed out, a net change of -1 holder.
  • The largest BioCardia buyer in Q4 2019 was UBS Group, an estimated $11.2K added.
  • The largest BioCardia seller in Q4 2019 was Goldman Sachs, an estimated $71K sold.

Based on aggregated 13F filings for Q4 2019.